140 results about "Non steroidal" patented technology

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a pH response hydrogel microneedle, which comprises a microneedle substrate, microneedle tips are arranged on the microneedle substrate, the height of the microneedle tips is 100-1600 microns, the diameter of the tip ends of the microneedle tips is 5-15 microns, and the density of the microneedle tips is 200-1000 pieces per square centimeter. The preparation method comprises the following steps: preparing a hyaluronic acid solution for the microneedle substrate, preparing a methacrylated chondroitin sulfate solution for the microneedle tip, preparing methacrylated orthoester, preparing orthoester, preparing a non-steroidal anti-inflammatory drug solution, preparing a microneedle tip solution, preparing the microneedle and demolding the microneedle to prepare the complete soluble microneedle patch. The invention has the advantages of high drug efficiency, high efficiency in dissolving fat / water drugs, and long-acting slow release.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a green synthesis process of non-steroidal loxoprofen sodium, and relates to the field of loxoprofen sodium synthesis. A water / organic two-phase free radical bromination and functionalized Pd-Ru / NH2-ZIF-8 catalysis one-step hydrogenation degreasing-tert-butyl ester removal path is adopted. The catalyst is modified by a thiol ligand and cooperates with a chiral inducer to construct a Pd-Ru bimetallic active site, so that the product purity and the product yield are effectively improved, and the catalyst can be repeatedly used. The method is environment-friendly and efficient in process and suitable for industrial application.

The application provides a method for analyzing the synergistic mechanism of hepatotoxicity and nephrotoxicity of non-steroidal anti-inflammatory drugs. The method comprises the following steps: preliminary toxicity prediction of NSAIDs and collection of toxicity target points, collection of liver and kidney disease target points, then cross and screening of the target points to obtain core target points and common core target points of NSAIDs induced liver and kidney diseases, and then constructing a protein interaction network of the common core target points; enrichment analysis of the common core target points to obtain the common action pathway of NSAIDs induced liver and kidney diseases; finally, further screening of the common core target points to obtain the key target points of NSAIDs induced liver and kidney diseases, and verification by using molecular docking technology. Compared with the traditional method, the advantages of the method are: first, the method does not depend on large-scale patient clinical data and a large number of animal or cell experiments, avoiding the ethical controversy in animal experiments and human experiments; second, the method can identify the potential cross-pathway and synergistic toxicity mechanism when a compound triggers multiple diseases, which is helpful for more comprehensive evaluation of the toxicity risk of NSAIDs.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor.The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM. The nonsteroidal SGRM may comprise: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.

This specification describes softgel capsules comprising a filler material and a shell composition. The filler material may contain alkali metal salts of NSAIDs and acetaminophen, but may not contain povidone. The shell composition may contain a film-forming material. The softgel capsules may have at least about 99% assay stability at room temperature after 12 months.

The present invention provides a tegoprazan sugar acid salt and a preparation method therefor, the salt being pharmaceutically usable for gastroesophageal disease, gastroesophageal reflux disease, gastritis, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcer, non-erosive reflux disease (NERD) and the like. The tegoprazan sugar acid salt of the present invention has excellent water solubility and stability of tegoprazan, and thus can be particularly useful as a pharmaceutical injection preparation.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The present invention relates to a patch (1) for the topical treatment of sinusitis in a person to be treated, the patch (1) comprising at least one active section (2) with at least one active ingredient and at least one adhesive section (3), wherein the patch (1) is designed to be at least partially, preferably completely, occlusive in the at least one active section (2) and / or in the at least one adhesive section (3), wherein it is provided according to the invention that the at least one active section (2) contains a therapeutically effective amount of a non-steroidal anti-inflammatory drug and / or its physiologically compatible compounds / salts and / or physiologically compatible chemical derivatives as the at least one active ingredient, and that the patch (1) has a shape that is adapted to the anatomical conditions of the application site, wherein the application site is in the face in the area of ​​at least one of the paranasal sinuses,preferably located in the area of ​​the cheek of the person to be treated, in order to enable targeted percutaneous treatment of the sinusitis.

Systems, methods, and computer programs disclosed herein relate to the determination of a dosage of a mineralocorticoid receptor antagonist (MRA) for a patient suffering from a disease that can be treated with an MRA.

The present invention discloses a method for alleviating gastrointestinal side effects resulting from the administration of pharmaceutical agents selected from the group including non-steroidal anti-inflammatory drugs (NSAIDs), glucagon-like peptide-1 (GLP-1) receptor agonists, gastric inhibitory polypeptide (GIP) receptor agonists, dual GIP / GLP-1 receptor co-agonists, and combinations thereof, by administering a composition containing colostrum product, bovine colostrum, or combinations thereof to a subject. The present invention discloses compositions and kits related to alleviating gastrointestinal side effects resulting from the administration of pharmaceutical agents selected from a group including non-steroidal anti-inflammatory drugs (NSAIDs), glucagon-like peptide-1 (GLP -1) receptor agonists, gastric inhibitory polypeptide (GIP) receptor agonists, dual GIP / GLP -1 receptor co-agonists, and combinations thereof. This method provides a novel approach to mitigate gastrointestinal side effects associated with the use of these pharmaceutical agents, enhancing patient comfort and compliance during treatment.

Methods are described for treating a cancer patient with a neutrophil-to-lymphocyte ratio (NLR) greater than 3, comprising administering a nonsteroidal glucocorticoid receptor antagonist (GRA) to the cancer patient, effective in reducing the patient's NLR. The methods include administering a nonsteroidal GRA and cancer therapy to the cancer patient, effective in reducing the patient's NLR and enhancing the cancer patient's treatment. The GRA may be administered orally. The nonsteroidal GRA may be a nonsteroidal compound comprising a fused azadecalin heteroarylketone structure (e.g., relacorylant) or a fused octahydro azadecalin structure (e.g., exicorylant).Cancer treatment may include chemotherapy, immunotherapy, radiation therapy, administration of an anti-angiogenic agent, administration of a growth factor inhibitor, and surgery. These methods can enhance cancer treatment, improve the prognosis of cancer patients, improve cancer patient survival, and provide beneficial clinical effects and advantages for the patient.

Disclosed herein are novel IEX-NSAID complexes comprising a nonsteroidal anti-inflammatory drug (NSAID) or a salt thereof bound to an ion-exchange (IEX) resin, as well as liquid dosage forms thereof, and their use for treating, ameliorating, preventing, or reducing the severity of numerous conditions, or their symptoms, for with NSAID are the prescribed treatment. Also disclosed herein are methods for making the aforementioned IEX-NSAID complexes, and liquid dosage forms thereof.

The present invention relates to the medical device and ophthalmological industry, as well as related fields such as dermatology and cosmetics, since the formulation includes natural neuroprotective components. The invention describes an iontophoretic delivery of cannabinoid-based formulations designed for ophthalmic conditions, that comprise pharmaceutically acceptable charged vehicles, including but not limited to cationic surfactants, cyclodextrins, nanoparticles and microspheres, emulsions or liposomes, with control the size distribution, potential, osmolality and pH. In a further embodiment of the invention, the intraocular composition proposed further comprises one or more synergistic agents, including but not limited to neuropeptides, exosomes, mitochondrial-derived peptides, complement inhibitors, senolytics, autophagy enhancers, antioxidants, saffron, and non-steroidal anti-inflammatory pharmaceutical drugs with pharmaceutically acceptable charged vehicle.

The invention relates to a preparation method of a diamine chiral resolving agent. The method comprises the following steps: by taking chiral alpha-amino acid as a raw material, reacting the chiral alpha-amino acid with (Boc) 2O and alkali in a solvent to obtain Boc-protected amino acid; in a solvent, the Boc-protected amino acid and secondary amine are subjected to catalysis of a condensing agent and alkali to obtain Boc amino-protected secondary amide; dissolving the Boc amino protected secondary amide in an organic solvent, and removing a Boc protecting group under an acidic condition to obtain chiral alpha-amino secondary amide; and reducing the chiral alpha-amino secondary amide into amine under the action of a reducing agent to obtain chiral amino secondary amine, namely the target product diamine chiral resolving agent. The chiral alpha-amino acid required by the preparation method is cheap and easy to obtain, the operation is simple, the obtained chiral diamine resolving agent is novel in structure, the variety of alkaline resolving agents is enriched, and the chiral diamine resolving agent is applied to resolution of racemic propionic acid compounds such as non-steroidal anti-inflammatory drugs ibuprofen and flurbiprofen and has practicability.

To provide a drug-induced renal dysfunction relieving agent that enables inhibition or mitigation of renal dysfunction resulting from administration of a drug.SOLUTION: A drug-induced renal dysfunction relieving agent comprising, as an active ingredient, a dopamine D2-like receptor agonist. The dopamine D2-like receptor may be DRD2. The dopamine D2-like receptor agonist may be at least one selected from the group consisting of quinpirole, dopamine, ropinirole, and bromocriptine. The agent is preferably administered to a patient having drug-induced renal dysfunction caused by administration of a platinum-based anticancer agent, an antibacterial agent, an antiviral agent, a contrast medium, or an NSAIDs.SELECTED DRAWING: None

There is provided a compound of formula I, X-Y (I) wherein: Y comprises a peptide fragment of formula IV, [Ala] m-[Lys-V] n-Lys-V (IV) wherein m represents 0 or 1, n represents the integer 0, 1, 2, 3 or 4, and each V independently represents a sequence of 2 to 4 amino acids wherein the amino acids are selected from one or more of the group consisting of Lys, Pro, Hyp, diHyp, Thr, pThr, DOPA, Tyr and Ser; and X represents at least one optional substituent selected from the group consisting of: (i) a lipid selected from the group consisting of vitamin A, vitamin E, cholesterol and fatty acids comprising one or more carboxylic acid groups, 1 to 50 carbons and / or one or more cyclic rings, said lipids being linear or branched, saturated or unsaturated with between 1 and 10 carbon-carbon double bonds and / or substituted with between 1 and 10-OH groups, or a derivative of any of these lipids; and / or (ii) a non-steroidal anti-inflammatory agent, which compounds may be used in medicine, including as pharmaceutical excipients, adhesives and film-forming materials, and / or may be used in the treatment of conditions characterized by inflammation, including wounds, burns and mucosal disorders such as skin diseases, oral diseases, gynecological diseases and IBD.

The invention belongs to the technical field of medicines, and particularly relates to a preparation method and application of a self-assembled conjugate of a non-steroidal anti-inflammatory drug and irinotecan. Water-insoluble non-steroidal anti-inflammatory drugs (ibuprofen, oxaprozin, naproxen, indometacin and the like) are introduced into a water-soluble anti-tumor drug irinotecan through esterification reaction and are self-assembled into nano particles in an aqueous solution, and then the self-assembled nano conjugate with an anti-tumor effect is formed. The inhibition activity of the nano particles prepared by the method on tumor cells is far better than that of irinotecan and a corresponding physical mixture of a non-steroidal anti-inflammatory drug and irinotecan, cancer cell proliferation can be accurately blocked by synergistically inhibiting protein expression of COX-2 and Topo I, particularly, the inhibition effect on Topo I is better, the anti-tumor treatment effect is greatly improved, and the nano particles have good application prospects. And a more efficient scheme is provided for tumor treatment.

Drug-loaded microspheres containing both a steroidal anti-inflammatory drug and a non-steroidal anti-inflammatory drug and injectable formulations containing the microspheres for sustained release of both drugs are disclosed. Methods of making such drug-loaded microspheres, formulations, and use of them for treating pains and inflammations, especially those caused by rheumatoid arthritis or osteoarthritis using such microspheres and formulations are also described.

The invention belongs to the technical field of wound dressings, and discloses a hydrogel dressing with antibacterial and scar-preventing effects and a preparation method thereof.3-fluoro-4-carboxyphenylboronic acid grafted chitosan oligosaccharide is introduced, phenylboronic acid bonds are matched with a large number of catechol structures in a tannic acid solution to form dynamic boron ester bonds, and the dynamic boron ester bonds are grafted to the chitosan oligosaccharide; the preparation method comprises the following steps: carrying out joint response with supramolecular forces such as hydrogen bonds to form a network gel structure, enabling boron ester bonds to respond to a high ROS level of a wound microenvironment and an acidic environment caused by bacterial infection to break, so as to efficiently release cyclooxygenase-2 selective non-steroidal anti-inflammatory drug celecoxib, and enabling the vinipofen liposome to be limited by a relatively large volume, so that the vinipofen liposome has a good anti-inflammatory effect. The time of staying in the dressing is longer, and continuous and stable release can be maintained in the whole wound healing process range, so that the effects of on-demand inflammation regulation and control and long-acting mechanical response regulation and control are achieved.

The invention relates to a method for purifying a non-steroidal GnRH agonist polypeptide, in particular to a method, a system and a product for preparing water-soluble high-purity delorelin acetate. According to the invention, a raw material medicine existing in a high acetate form is obtained through preparative-grade reversed-phase chromatography purification, ion conversion on a column and optimization of salt conversion and freeze-drying pretreatment. The HPLC purity of the product is greater than or equal to 98.5%, the acetic acid content is about 13.9%-14.7% (w / w), the solubility in pure water is greater than or equal to 120 mg / mL, and the product is kept clear for 24 hours; the retention time is consistent with that of a commercial reference substance. And compared with a contrast, the method has the advantages that the high-purity fraction yield is obviously improved, impurities and non-target pair ion residues are reduced, and the method is suitable for industrial amplification and preparation development.

The present invention relates to microspheres and a preparation method therefor, the microspheres comprising: ropivacaine, a salt thereof, a hydrate or a solvate thereof, which have the effect of regulating acute pain after surgery; a nonsteroidal anti-inflammatory drug (NSAID); and a biodegradable polymer. The present invention provides a pharmaceutical composition for providing sustained and effective analgesic effects of ropivacaine and a nonsteroidal anti-inflammatory agent. The preparation of the present invention is applicable to all diseases in which acute pain control effects can be exhibited, and, particularly, has an improved sustained-release profile of ropivacaine and a nonsteroidal anti-inflammatory agent and simultaneously controls the release of the two drugs, can continuously provide effective analgesic effects, and can significantly increase medication compliance. In addition, conversion from a liquid solution to dry powder proceeds in a single step, and thus the microsphere preparation method of the present invention has advantages in terms of cost, scaling up, and process simplification.

Provided herein are compositions suitable for treating chemically induced eye damage comprising (a) a nonsteroidal anti-inflammatory drug (NSAID), (b) a histone deacetylase (HDAC) inhibitor and (c) an angiotensin converting enzyme (ACE) inhibitor and, optionally, (d) a water-soluble vitamin. Methods of using provided compositions to treat ocular toxicity and corneal damage following exposure to chemical agents (e.g., mustard gas) are also provided.